[1]
Bianco J, Bastiancich C, Jankovski A, des Rieux A, Preat V, Danhier F. On glioblastoma and the search for a cure: Where do we stand? Cell Mol Life Sci 2017; 74(13): 2451-66.
[2]
Gaelzer MM, Coelho BP, de Quadros AH, et al. Phosphatidylinositol 3-Kinase/AKT pathway inhibition by doxazosin promotes glioblastoma cells death, upregulation of p53 and triggers low neurotoxicity. PLoS One 2016; 11(4): e0154612.
[3]
Staudacher I, Jehle J, Staudacher K, et al. HERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells. PLoS One 2014; 9(2): e88164.
[4]
de la Chica-Rodriguez S, Cortes-Denia P, Ramirez-Exposito MJ, Martinez-Martos JM. Effects of alpha1-adrenergic receptor blockade by doxazosin on renin-angiotensin system-regulating aminopeptidase and vasopressin-degrading activities in male and female rat thalamus. Horm Metab Res 2007; 39(11): 813-7.
[5]
de la Chica-Rodriguez S, Cortes-Denia P, Ramirez-Exposito MJ, et al. In vivo administration of doxazosin in rats highly decreases serum circulating levels of testosterone through a mechanism involving the testicular renin-angiotensin system. Int J Androl 2008; 31(3): 364-70.
[6]
de la Chica-Rodriguez S, Cortes-Denia P, Ramirez-Exposito MJ, et al. Doxazosin blockade of alpha 1-adrenergic receptors increases rat serum progesterone levels: A putative role of ovarian angiotensin III in steroidogenesis. Fertil Steril 2007; 88(4)(Suppl.): 1071-5.
[7]
Saniger MA, Ramirez-Exposito MJ, de la Chica S, Carrera-Gonzalez MP, Mayas MD, Manuel Martinez-Martos J. Alpha-1-adrenergic receptor blockade modifies insulin-regulated aminopeptidase (IRAP) activity in rat prostate and modulates oxytocin functions. Drug Metab Lett 2011; 5(3): 192-6.
[8]
Mayas MD, Ramirez-Exposito MJ, Carrera MP, Cobo M, Martinez-Martos JM. Renin-angiotensin system-regulating aminopeptidases in tumor growth of rat C6 gliomas implanted at the subcutaneous region. Anticancer Res 2012; 32(9): 3675-82.
[9]
Wright JW, Harding JW. The brain renin-angiotensin system: A diversity of functions and implications for CNS diseases. Pflugers Arch 2013; 465(1): 133-51.
[10]
Escobar E, Rodriguez-Reyna TS, Arrieta O, Sotelo J. Angiotensin II, cell proliferation and angiogenesis regulator: Biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2004; 2(4): 385-99.
[11]
Arrieta O, Pineda-Olvera B, Guevara-Salazar P, et al. Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis. Br J Cancer 2008; 99(1): 160-6.
[12]
Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, et al. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 2004; 90(5): 1059-68.
[13]
Juillerat-Jeanneret L, Lohm S, Hamou MF, Pinet F. Regulation of aminopeptidase A in human brain tumor vasculature: Evidence for a role of transforming growth factor-beta. Lab Invest 2000; 80(6): 973-80.
[14]
Genest J, Cantin M, Garcia R, et al. Extrarenal angiotensin-forming enzymes. Clin Exp Hypertens A 1983; 5(7-8): 1065-80.
[15]
Johnston CI. ACE inhibitors and the kidney. Nephron 1990; 55(Suppl. 1): 1-2.
[16]
Ramirez-Exposito MJ, Martinez JM, Prieto I, Alba F, Ramirez M. Comparative distribution of glutamyl and aspartyl aminopeptidase activities in mouse organs. Horm Metab Res 2000; 32(5): 161-3.
[17]
Kambayashi Y, Bardhan S, Takahashi K, et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 1993; 268(33): 24543-6.
[18]
Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993; 268(33): 24539-42.
[19]
Stegbauer J, Coffman TM. New insights into angiotensin receptor actions: From blood pressure to aging. Curr Opin Nephrol Hypertens 2011; 20(1): 84-8.
[20]
Blair-West JR, Coghlan JP, Denton DA, Funder JW, Scoggins BA, Wright RD. The effect of the heptapeptide (2-8) and hexapeptide (3-8) fragments of angiotensin II on aldosterone secretion. J Clin Endocrinol Metab 1971; 32(4): 575-8.
[21]
Ramirez-Exposito MJ, Martinez-Martos JM. Anti-inflammatory and antitumor effects of hydroxytyrosol but not oleuropein on experimental glioma in vivo. A putative role for the renin-angiotensin system. Biomedicines 2018; 6.
[22]
Illan-Cabeza NA, Jimenez-Pulido SB, Ramirez-Exposito MJ, et al. Structural and theoretical studies on rhodium and iridium complexes with 5-nitrosopyrimidines. Effects on the proteolytic regulatory enzymes of the renin-angiotensin system in human tumoral brain cells. J Inorg Biochem 2015; 143: 20-33.
[23]
Illan-Cabeza NA, Garcia-Garcia AR, Martinez-Martos JM, Ramirez-Exposito MJ, Moreno-Carretero MN. Antiproliferative effects of palladium(ii) complexes of 5-nitrosopyrimidines and interactions with the proteolytic regulatory enzymes of the renin-angiotensin system in tumoral brain cells. J Inorg Biochem 2013; 126: 118-27.
[24]
Ramirez-Exposito MJ, Mayas-Torres MD, Carrera-Gonzalez MP, et al. Silver(I)/6-hydroxyiminolumazine compounds differently modify renin-angiotensin system-regulating aminopeptidases A and N in human neuroblastoma and glioma cells. J Inorg Biochem 2014; 138: 56-63.
[25]
Illan-Cabeza NA, Garcia-Garcia AR, Martinez-Martos JM, Ramirez-Exposito MJ, Pena-Ruiz T, Moreno-Carretero MN. A potential antitumor agent, (6-amino-1-methyl-5-nitrosouracilato-N3)-triphenylphosphine-gold(I): Structural studies and in vivo biological effects against experimental glioma. Eur J Med Chem 2013; 64: 260-72.
[26]
Ni L, Feng Y, Wan H, et al. Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways. Oncol Rep 2012; 27(3): 783-90.
[27]
George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: Old dog, new tricks. Nat Rev Cancer 2010; 10(11): 745-59.
[28]
Sim MK, Choo MH, Qiu XS. Degradation of angiotensin I to [des-Asp1]angiotensin I by a novel aminopeptidase in the rat hypothalamus. Biochem Pharmacol 1994; 48(5): 1043-6.
[29]
Fujimura H, Ino K, Nagasaka T, et al. Aminopeptidase A expression in cervical neoplasia and its relationship to neoplastic transformation and progression. Oncology 2000; 58(4): 342-52.
[30]
Teranishi J, Ishiguro H, Hoshino K, Noguchi K, Kubota Y, Uemura H. Evaluation of role of angiotensin III and aminopeptidases in prostate cancer cells. Prostate 2008; 68(15): 1666-73.
[31]
Xu J, Fan J, Wu F, et al. The ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Pleiotropic Roles in Cancer. Front Physiol 2017; 8: 276.
[32]
Liu B, Liu Y, Jiang Y. Podocalyxin promotes glioblastoma multiforme cell invasion and proliferation by inhibiting angiotensin-(1-7)/Mas signaling. Oncol Rep 2015; 33(5): 2583-91.
[33]
Barrett AJ, Rawlings ND, Woessner JF. Handbook of proteolytic enzymes. Elsevier Academic Press: Amsterdam; Boston, MA 2004.
[34]
Axen A, Lindeberg G, Demaegdt H, Vauquelin G, Karlen A, Hallberg M. Cyclic insulin-regulated aminopeptidase (IRAP)/AT4 receptor ligands. J Pept Sci 2006; 12(11): 705-13.
[35]
Yang H, Zeng XJ, Wang HX, et al. Angiotensin IV protects against angiotensin II-induced cardiac injury via AT4 receptor. Peptides 2011; 32(10): 2108-15.
[36]
Dixon J, Kaklamanis L, Turley H, et al. Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol 1994; 47(1): 43-7.
[37]
Varona A, Blanco L, Lopez JI, et al. Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. Am J Physiol Renal Physiol 2007; 292(2): F780-8.
[38]
Wang D, Huang HJ, Kazlauskas A, Cavenee WK. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 1999; 59(7): 1464-72.
[39]
Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: A review. Surg Neurol 1998; 49(2): 189-95. discussion 96.
[40]
Schmidt NO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999; 84(1): 10-8.
[41]
El Sharkawi FZ, El Shemy HA, Khaled HM. Possible anticancer activity of rosuvastatine, doxazosin, repaglinide and oxcarbazepin. Asian Pac J Cancer Prev 2014; 15(1): 199-203.
[42]
Petty A, Myshkin E, Qin H, et al. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One 2012; 7(8): e42120.
